Wechselwirkungen · Trecondi
Trecondi 1 g powder for solution for infusion Trecondi 5 g powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 5
HOS-141337 · Präparat HOS-098634
Detailed in vitro studies did not completely exclude potential interactions between high plasma concentrations of treosulfan and CYP3A4, CYP2C19, or P-glycoprotein (P-gp) substrates. Physiologically-based pharmacokinetic modelling predicted a weak (AUC ratio ≥ 1.25 and < 2) to moderate (AUC ratio ≥ 2 and < 5) interaction for CYP3A4, a weak interaction for CYP2C19, and a negligible (AUC ratio < 1.25) interaction for P-gp. Therefore, medicinal products with a narrow therapeutic index (e.g. tacrolimus) that are substrates for CYP3A4 or CYP2C19 should not be given during treatment with treosulfan. Considering overall timing of treatments and the respective pharmacokinetic properties of concomitantly used medicinal products (e.g. half-life), the interaction potential can be reduced to “no interaction” (AUC ratio < 1.25), if all concomitantly used medicinal products are dosed 2 hours before or 8 hours after the 2-hour intravenous infusion of treosulfan.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tacrolimus (HOS-085202)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-12T11:54:00Z · SHA-256 10322ff4fd20d5b03cbd2c8d747d04b9b08c53e7af9f026b1499364424dfbe6d · Passage 922fdfd940b7fe48b5216712b83b54f3bf674c572e01020d11c775dacd2b1d71 · Zeichen 70–1031 im Abschnitt